XOMA initiates study By: MarketMinute.com Stock News October 27, 2015 at 18:49 PM EDT XOMA Corp. (Nasdaq: XOMA) initiated a Phase 2 proof-of-concept study for XOMA 358 in patients with congenital hyperinsulinism sending the stock price up 24 cents to close at $1.31.